Clinical trials: Mild Hypertension
- Condition Mild Hypertension
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Prehypertension
Effect and Safety of Marealis RPC (Refined Peptide Concentrate) in Mild or Moderate Hypertensive Subjects
Hypertension is an important risk factor of cardiovascular (CVD) and renal diseases. Epidemiological studies show that there is a direct relationship between blood pressure and CVD, and cardiovascular mortality increases…
- Trial name
- NCT01974570
- Testing
- Marealis refined peptide concentrate
- Where
- 13 sites in United States, Canada and 2 more
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- KGK Science Inc.
Subjects With Mild Hypertension
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of HRS-9563 in Subjects With Mild Hypertension: a Randomized, Double-blind, Placebo-controlled Phase I Study.
To evaluate the safety and tolerability of a single subcutaneous injection of HRS-9563 in hypertensive subjects
- Trial name
- NCT07117474
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Essential Hypertension, Healthy Volunteers
Phase 1 Clinical Study of MWX401 Injection in Chinese Healthy Participants and Participants With Mild Hypertension
This is a single-center, randomized, double-blind, placebo-controlled, single ascending-dose phase 1 clinical study, aimed at evaluating the safety, tolerability, PK, PD and immunogenicity of single subcutaneous administration of…
- Trial name
- NCT07803835
- Testing
- MWX401 1, MWX401 2, MWX401 3
- Where
- China
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Pre-hypertension
A Study to Investigate the Effect of a Nitric Oxide Supplementation on Pre- and Mildly Hypertensive Adults
This study will investigate the effect of a nitric oxide supplementation product, Neo40 Daily®, on blood pressure in pre-hypertensive and mildly hypertensive adults.
- Trial name
- 15NBHN (NCT02679248)
- Testing
- Neo40 Daily®
- Where
- 2 sites in Canada
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- KGK Science Inc.
Uncontrolled Hypertension
A Phase I Trial of QLS1410 in Healthy Chinese Adults and Participants With Mild Essential Hypertension
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and food effect of single and multiple ascending doses of QLS1410 in healthy Chinese adults and participants with mild…
- Trial name
- NCT07152444
- Testing
- QLS1410 (CYP11B2 inhibitor)
- Where
- China
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Healthy Adult, Hypertension
A Phase I Single and Multiple Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of HS-10522 in Healthy Chinese Participants and Chinese Participants With Mild Hypertension
The purpose of this study is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple oral doses of HS-10522 in healthy Chinese participants and Chinese participants with…
- Trial name
- NCT07609875
- Testing
- HS-10522
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Mild Hypertension
A Study to Evaluate the Safety of QCZ484 in Healthy and Mild Hypertensive Subjects
This is a randomized, double-blind, placebo-controlled study including Part A single ascending dose (SAD) in healthy subjects and Part B single dose in subjects with mild hypertension.
- Trial name
- NCT06905327
- Testing
- QCZ484
- Where
- 4 sites in Australia, New Zealand
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Primary Mild and Moderate Hypertension
Study on Human Mass Balance of SPH3127 Tablets
To quantitatively analyze the total radioactivity in the excreta of healthy male subjects after oral administration of [14C] SPH3127, and determine the cumulative excretion rate and main excretion routes of radioactive…
- Trial name
- NCT05593562
- Testing
- SPH3127
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Hypertension
A Study in Chinese Mild to Moderate Hypertensive Patients Comparing the Efficacy of Co-Diovan With Diovan.
Valsartan, an orally active angiotensin II receptor blocker, is registered in most countries worldwide for the treatment of hypertension. In China the usual recommended starting and maintenance dose is 80 mg o.d.
- Trial name
- NCT00250562
- Testing
- valsartan plus hydrochlorothiazide
- Where
- United States
- Volunteers
- 1,171 people, healthy volunteers welcome
- Sponsor
- Novartis
Open Angle Glaucoma
Combined Phacoemulsification With iStent Inject W Versus Hydrus for Mild to Moderate Open Angle Glaucoma
The goal of the study is to prospectively evaluate and compare Hydrus microstent to the iStent Inject Wide in combination with cataract surgery in patients with mild to moderate open angle glaucoma.
- Trial name
- NCT05583591
- Testing
- Combined cataract surgery with Hydrus microstent, Combined cataract surgery with iStent Inject W
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Diablo Eye Associates
Healthy Volunteers
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9035 in Healthy Adult Volunteers and Mildly Hypertensive Participants
The primary objective of the study is to: Evaluate the safety and tolerability of REGN5381 and REGN9035 administered alone or sequentially.
- Trial name
- NCT05291546
- Testing
- REGN9035, REGN5381
- Where
- 2 sites in Belgium, Germany
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Overweight and Obesity
Efficacy of Palatinose™ Versus Sucrose on Flow Mediated Dilation in Healthy Subjects With Mild Hypertension
To determine the efficacy of Palatinose versus sucrose on Flow Mediated Dilation (FMD) in healthy subjects with mild hypertension.
- Trial name
- NCT03986775
- Testing
- isomaltulose, sucrose
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Beneo-Institute
Symptomatic Neurogenic Orthostatic Hypertension, nOH
Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855
An open-label study to characterize the effects of mild, moderate, and severe Hepatic Impairment (HI) on the pharmacokinetics (PK) of ampreloxetine following a single oral dose in comparison with healthy volunteers with normal…
- Trial name
- NCT04200573
- Testing
- Ampreloxetine
- Where
- 2 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
Hypertension
The First-in-Human Study of GW906 Injection
This study is a randomized, double-blind, placebo-controlled, single-dose, dose-escalation trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GW906 in healthy subjects and subjects with mild…
- Trial name
- NCT07884461
- Testing
- GW906 injection
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Erectile Dysfunction, Pulmonary Arterial Hypertension
Study of the Pharmacokinetics and Safety of TPN171H Tablets in Subjects With Mild ,Moderate Hepatic Insufficiency and Normal Liver Function
The study aims to investigate and compare the effect of TPN171H on subjects with mild and moderate hepatic impairment compared to healthy subjects.
- Trial name
- NCT05185011
- Testing
- TPN171H
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Vigonvita Life Sciences
Hypertension,Essential
Study of SGB-3908 in Healthy Subjects and Mildly Hypertensive Subjects
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) effects of SGB-3908 in healthy subjects and mildly hypertensive subjects.
- Trial name
- NCT06501586
- Testing
- SGB-3908
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Suzhou Sanegene Bio Inc.